Case report highlights GFAP myelitis in a lung adenocarcinoma patient after pembrolizumab treatment, suggesting monitoring needs.
To report a case of a 58-year-old female with history of lung adenocarcinoma who developed GFAP longitudinally extensive myelitis secondary to immune-checkpoint inhibitor (ICI) pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Maisenbacher et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: